Study on the Efficacy of Jingangteng Combined with Doxycycline in the Treatment of Chronic Pelvic Inflammatory Disease and the Clinical Manifestations of the Influence of Inflammatory Factors

Chronic pelvic inflammatory disease (CPID) is a common gynecological infectious disease in women of childbearing age. It is characterized by a long course and is difficult to cure. Traditional antibiotic treatment has limitations. This prospective, randomized, controlled clinical trial evaluated the clinical efficacy of jingangteng tung combined with doxycycline in the treatment of CPID and its effects on inflammatory factors. Sixty patients were randomly divided into an experimental group (combination therapy group) and a control group (doxycycline monotherapy group), with 30 patients in each group. Results showed that the total effective rate in the experimental group was 93.3%, significantly higher than the 76.7% in the control group (P < 0.05). After treatment, serum levels of the inflammatory factors IL-6, TNF-α, and CRP in the experimental group were significantly lower than those in the control group, while levels of the anti-inflammatory factor IL-10 were significantly higher in the control group (P < 0.01). Combination therapy exerts a synergistic anti- inflammatory effect by inhibiting the release of pro-inflammatory factors and promoting the expression of anti- inflammatory factors, with a good safety profile. Studies have shown that the combination of Vatica chinensis and doxycycline is safe and effective in treating CPID, and can significantly relieve symptoms, regulate inflammatory responses, and reduce the risk of disease recurrence and sequelae, providing a clinical basis for the integrated treatment of CPID with traditional Chinese and Western medicine.